Journal: Cell / Year: 2021 Title: Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Authors: Emanuele Andreano / Emanuele Nicastri / Ida Paciello / Piero Pileri / Noemi Manganaro / Giulia Piccini / Alessandro Manenti / Elisa Pantano / Anna Kabanova / Marco Troisi / Fabiola Vacca / ...Authors: Emanuele Andreano / Emanuele Nicastri / Ida Paciello / Piero Pileri / Noemi Manganaro / Giulia Piccini / Alessandro Manenti / Elisa Pantano / Anna Kabanova / Marco Troisi / Fabiola Vacca / Dario Cardamone / Concetta De Santi / Jonathan L Torres / Gabriel Ozorowski / Linda Benincasa / Hyesun Jang / Cecilia Di Genova / Lorenzo Depau / Jlenia Brunetti / Chiara Agrati / Maria Rosaria Capobianchi / Concetta Castilletti / Arianna Emiliozzi / Massimiliano Fabbiani / Francesca Montagnani / Luisa Bracci / Giuseppe Sautto / Ted M Ross / Emanuele Montomoli / Nigel Temperton / Andrew B Ward / Claudia Sala / Giuseppe Ippolito / Rino Rappuoli / Abstract: Human monoclonal antibodies are safe, preventive, and therapeutic tools that can be rapidly developed to help restore the massive health and economic disruption caused by the coronavirus disease 2019 ...Human monoclonal antibodies are safe, preventive, and therapeutic tools that can be rapidly developed to help restore the massive health and economic disruption caused by the coronavirus disease 2019 (COVID-19) pandemic. By single-cell sorting 4,277 SARS-CoV-2 spike protein-specific memory B cells from 14 COVID-19 survivors, 453 neutralizing antibodies were identified. The most potent neutralizing antibodies recognized the spike protein receptor-binding domain, followed in potency by antibodies that recognize the S1 domain, the spike protein trimer, and the S2 subunit. Only 1.4% of them neutralized the authentic virus with a potency of 1-10 ng/mL. The most potent monoclonal antibody, engineered to reduce the risk of antibody-dependent enhancement and prolong half-life, neutralized the authentic wild-type virus and emerging variants containing D614G, E484K, and N501Y substitutions. Prophylactic and therapeutic efficacy in the hamster model was observed at 0.25 and 4 mg/kg respectively in absence of Fc functions.
History
Deposition
Feb 22, 2021
-
Header (metadata) release
Mar 9, 2022
-
Map release
Mar 9, 2022
-
Update
Mar 9, 2022
-
Current status
Mar 9, 2022
Processing site: RCSB / Status: Released
-
Structure visualization
Movie
Surface view with section colored by density value
In the structure databanks used in Yorodumi, some data are registered as the other names, "COVID-19 virus" and "2019-nCoV". Here are the details of the virus and the list of structure data.
Jan 31, 2019. EMDB accession codes are about to change! (news from PDBe EMDB page)
EMDB accession codes are about to change! (news from PDBe EMDB page)
The allocation of 4 digits for EMDB accession codes will soon come to an end. Whilst these codes will remain in use, new EMDB accession codes will include an additional digit and will expand incrementally as the available range of codes is exhausted. The current 4-digit format prefixed with “EMD-” (i.e. EMD-XXXX) will advance to a 5-digit format (i.e. EMD-XXXXX), and so on. It is currently estimated that the 4-digit codes will be depleted around Spring 2019, at which point the 5-digit format will come into force.
The EM Navigator/Yorodumi systems omit the EMD- prefix.
Related info.:Q: What is EMD? / ID/Accession-code notation in Yorodumi/EM Navigator
Yorodumi is a browser for structure data from EMDB, PDB, SASBDB, etc.
This page is also the successor to EM Navigator detail page, and also detail information page/front-end page for Omokage search.
The word "yorodu" (or yorozu) is an old Japanese word meaning "ten thousand". "mi" (miru) is to see.
Related info.:EMDB / PDB / SASBDB / Comparison of 3 databanks / Yorodumi Search / Aug 31, 2016. New EM Navigator & Yorodumi / Yorodumi Papers / Jmol/JSmol / Function and homology information / Changes in new EM Navigator and Yorodumi